Jump to Main-Site Navigation

Investor Relations

Stock Information
Ticker SNTS
Exchange NASDAQ
Price $4.75
Change + 0.12
Volume 411,000
Jan 27, 2012 3:59 PM ET
Stock price graph
3 Mo.   6 Mo.   1 Yr.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs: budesonide MMX® for induction of remission of active ulcerative colitis, RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers' diarrhea, in addition to other earlier-stage development programs.


Events & Presentations

There are no upcoming events at this time.

View all events »


Featured Reports

HTML file   2010 Annual Report

PDF  2010 Form 10-K






Page 'Breadcrumb' Navigation:

Jump to Content